{
    "clinical_study": {
        "@rank": "31695", 
        "acronym": "TBF", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental", 
            "description": "Thiotepa 5 mg/kg/day on days -7, -6 (Total Dose 10 mg/kg)\nBusulfan (i.v.) 3.2 mg/kg on days -5,-4,-3 (Total Dose 9.6 mg/kg)\nFludarabin: 50 mg/m2/day on days -5,-4,-3 (Total Dose 150 mg/m2)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate progression free survival, transplant-related\n      morbidity (TRM) at day +100 and at +365, overall survival and incidence of acute and chronic\n      GVHD in refractory/early relapsed aggressive B-cell non Hodgkin lymphomas patients treated\n      with allogeneic Transplantation after a conditioning with Thiotepa, Busulfan and fludarabin."
        }, 
        "brief_title": "Thiotepa, Busulfan and Fludarabin", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas", 
        "condition_browse": {
            "mesh_term": [
                "Aggression", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patient inclusion criteria:\n\n          -  Patients with refractory/relapsed aggressive B-cell non Hodgkin lymphomas after\n             frontline therapy.\n\n          -  Patients with stable disease or partial or complete remission (PET-negative) after\n             salvage therapy\n\n          -  Patients younger than 65 years old\n\n          -  A fully HLA-identical sibling or matched unrelated donor is available. Patients with\n             one antigen mismatched donors can be considered\n\n          -  Patient must be competent to give consent.\n\n        Patient exclusion criteria:\n\n          -  Patients treated with an autologous transplant as salvage therapy\n\n          -  Patients with progressive lymphomas despite conventional therapies\n\n          -  Patients with progressive lymphomas despite conventional therapies\n\n          -  Uncontrolled CNS involvement with disease\n\n          -  Fertile men or women unwilling to use contraceptive techniques during and for 12\n             months following treatment\n\n          -  Females who are pregnant or breastfeeding\n\n          -  Organ dysfunction defined as follows:\n\n               -  Cardiac function: ejection fraction <30% or uncontrolled cardiac failure\n\n               -  Pulmonary: DLCO <40% predicted\n\n               -  Liver function abnormalities: elevation of bilirubin to > 3 mg/dl and/or\n                  transaminases >4x the upper limit of normal\n\n               -  Renal: creatinine clearance <50 cc/min (24 hour urine  collection)\n\n          -  Karnofsky performance score < 60%\n\n          -  Patients with poorly controlled hypertension despite multiple antihypertensives\n\n          -  Documented fungal disease that is progressive despite treatment\n\n          -  Viral infections: HIV positive patients.\n\n          -  Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In\n             addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a\n             HBV DNA test will be performed and if positive the subject will be excluded.\n\n          -  Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which\n             case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the\n             result\n\n          -  Psychiatric disorders or psychosocial problems which in the opinion of the primary\n             physician or Principal Investigator would place the patient at unacceptable risk from\n             this regimen.\n\n          -  Patients with active non-hematologic malignancies (except non-melanoma skin cancers).\n\n          -  Patients with a history of non-hematologic malignancies (except non-melanoma skin\n             cancers) currently in a complete remission, who are less than 5 years from the time\n             of complete remission, and have a >20% risk of disease recurrence.\n\n        Donor inclusion criteria:\n\n          -  Related or unrelated HLA identical donors who are in good health and have no\n             contra-indication to donation. One antigen HLA-mismatched (9/10 match) donors will\n             also be considered.\n\n          -  No contra-indication for the donor to collection by apheresis of mononuclear cells\n             mobilized by G-CSF at a dose of 10-12 mg/kg of body weight.\n\n          -  Donor must have adequate veins for leukapheresis or agree to placement of central\n             venous catheter (femoral, subclavian).\n\n        Donor exclusion criteria:\n\n          -  Age < 18 years.\n\n          -  Identical twin.\n\n          -  Pregnancy.\n\n          -  Infection with HIV.\n\n          -  Inability to achieve adequate venous access.\n\n          -  Known allergy to filgrastin (G-CSF).\n\n          -  Current serious systemic illness."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01786018", 
            "org_study_id": "TBF2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "intervention_name": "Thiotepa", 
                "intervention_type": "Drug", 
                "other_name": "TEPADINA\u00ae"
            }, 
            {
                "arm_group_label": "1", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug", 
                "other_name": "BUSILVEX\u00ae"
            }, 
            {
                "arm_group_label": "1", 
                "intervention_name": "Fludarabin", 
                "intervention_type": "Drug", 
                "other_name": "FLUDARA\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Thiotepa"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non Hodgkin lymphomas", 
            "Allogeneic Transplantation", 
            "Thiotepa", 
            "Busulfan", 
            "Fludarabin"
        ], 
        "lastchanged_date": "February 6, 2013", 
        "location": {
            "contact": {
                "email": "benedetto.bruno@unito.it", 
                "last_name": "Benedetto Bruno, MD", 
                "phone": "+390116336728"
            }, 
            "facility": {
                "address": {
                    "city": "Torino", 
                    "country": "Italy", 
                    "zip": "10126"
                }, 
                "name": "Citt\u00e0 della Salute e della Scienza di Torino"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial", 
        "overall_contact": {
            "email": "benedetto.bruno@unito.it", 
            "last_name": "Benedetto Bruno, MD", 
            "phone": "+390116336728"
        }, 
        "overall_contact_backup": {
            "email": "gismm2001@yahoo.com", 
            "last_name": "Benedetto Bruno, MD", 
            "phone": "+390116336728"
        }, 
        "overall_official": {
            "affiliation": "Divisione di Ematologia-Citt\u00e0 della Salute e della Scienza di Torino", 
            "last_name": "Benedetto Bruno, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01786018"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Ospedaliera San Giovanni Battista", 
            "investigator_full_name": "Benedetto Bruno", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Transplant-related morbidity (TRM) at day +100 and at +365", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Incidence of acute and chronic GVHD", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Azienda Ospedaliera San Giovanni Battista", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Azienda Ospedaliera San Giovanni Battista", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}